AT04A

**AT04A** is an investigational AFFiRiS active peptide immunotherapy for hypercholesterolemia. It is an AFFITOPE-based vaccine comprising a 10-amino-acid peptide mimic of the PCSK9 amino-acid 153–162 epitope, coupled to a carrier protein and formulated with aluminum hydroxide adjuvant. Subcutaneous immunization is intended to induce endogenous PCSK9-specific neutralizing antibodies, thereby preventing PCSK9-mediated downregulation of hepatic LDL receptors and increasing LDL cholesterol clearance. In the randomized Phase 1 AFF012 study, AT04A was immunogenic and demonstrated LDL cholesterol lowering in high antibody responders. ([biospace.com](https://www.biospace.com/affiris-positive-phase-1-results-with-immunotherapies-targeting-pcsk9-to-treat-hypercholesterolemia-published-by-the-european-journal-of-clinical-pharmacology))

Brand names

AFFITOPE

Other names

AFFITOPE AT04A